Pilot Project Abstract - Tyner, Jeff, PhD
Jeff Tyner, PhD, Post Doctorate Fellow, Hematology/Oncology at OHSU: “Tyrosine Kinases as Targets for Therapy in Pediatric Acute Lymphoblastic Leukemia”
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, comprising 24% of all childhood malignancies. Although great strides have been made in the identification of biologic markers to risk stratify treatment, one-third of patients will have resistant disease and eventually succumb to their leukemia. To improve therapy, disease-causing gene targets must first be identified, and then drugs to modulate these targets can be employed. This strategy of targeted intervention may overcome treatment obstacles to our current therapies. We have employed RNAi technology to demonstrate that a functional screen can rapidly identify target genes crucial for viability of cell lines derived from cancer patients as well as primary patient samples. This technology allows for rapid target identification that can be used to tailor therapy for individual patients.